AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06175975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
Description: The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
Study NCT05310656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Empowerment Programme
Description: Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost intracameral implant exchanged at Month 21
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost intracameral implant exchanged at Month 18
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
Study NCT06079658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss
Description: This intervention seeks to investigate two different caloric restriction protocol on fat mass.
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost intracameral implant exchanged at Month 15
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
Study NCT05947903 — intervention group
Intervention type: OTHER
Intervention: Administration of the EUonQoL-Kit - Active Treatment questionnaire
Description: Electronic questionnaire to be administered to patients in active treatment.
Study NCT05947903 — intervention group
Intervention type: OTHER
Intervention: Administration of the EUonQoL-Kit - Survivors questionnaire
Description: Electronic questionnaire to be administered to cancer survivors.
Study NCT05231122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05231122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05947903 — intervention group
Intervention type: OTHER
Intervention: Administration of the EUonQoL-Kit - Palliative Care questionnaire
Description: Electronic questionnaire to be administered to patients in palliative care.
Study NCT05231122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06310993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise programme is the intervention for this study
Study NCT06641778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
Study NCT05497206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System
Description: Total Hip Arthroplasty
Study NCT06405412 — intervention group
Intervention type: OTHER
Intervention: MUST malnutrition score
Description: MUST malnutrition score
Study NCT03995043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
Study NCT03995043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Support
Description: Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
Study NCT03995043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to contraception
Description: Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
Study NCT05735158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB105
Description: Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
Study NCT05735158 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matched excipient gel
Study NCT05049681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
Study NCT04810455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purrble
Description: The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time.
Study NCT04810455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control toy
Description: The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
Study NCT05141786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT05584020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Repair
Description: Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
Study NCT05049681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
Study NCT05049681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg, q.d.po
Study NCT05584020 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ACL Reconstruction
Description: Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
Study NCT05158699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: Bromfenac topical eye drops (Yellox)
Study NCT05158699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone topical eye drops
Study NCT05158699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
Study NCT05804097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
Study NCT05158699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
Description: Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
Study NCT06174272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Care Program
Description: Intensive monitoring post discharge for cirrhosis and fluid overload
Study NCT05299671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video consultation
Description: During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
Study NCT04516434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurometer Neurotron CPT
Description: All participants will undergo CPT testing. A Neurotron catheter (12-French) with electrode will be inserted through the urethra into the bladder. The catheter balloon will be inflated and positioned at the urethrovesical junction to stimulate the urethra 10-14 mm from the bladder neck. For bladder stimulation, the catheter balloon will be deflated and the catheter will be advanced into the bladder. The device will deliver sine wave stimulus pulses at 5, 250, and 2,000 Hz. CPT will be established using an automated forced choice paradigm by the method of levels. Testing order of the bladder and urethra will be randomized between participants.
Study NCT04516434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystometry
Description: After bladder stimulation or during intraurethral stimulation, cystometry will be performed to assess bladder sensation and storage. A dual-chamber 8-French catheter will be passed through the urethra into the bladder for retrograde filling. A second 8-French catheter will be placed in the vagina to measure intra-abdominal pressure. A stimulation electrode catheter will only be inserted in the intraurethral stimulation arm. EMG pads will then be placed at 3 and 9 o'clock on each side of the perineum. The bladder will then be filled with room-temperature sterile saline solution in a retrograde fashion using a pump. Bladder sensation and urgency will be assessed while filling.
Study NCT04516434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-flow study
Description: A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
Study NCT06146205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral approach
Description: The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
Study NCT06146205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPAIRE
Description: The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
Study NCT05737849 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.
Study NCT06223919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LC16m8
Description: LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses
Study NCT06223919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC16m8
Description: LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses
Study NCT06450080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI and MRS acquisitions
Description: All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
Study NCT06450080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and MRS acquisitions
Description: All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
Study NCT05731323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
Study NCT05731323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulator
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
Study NCT05008562 — intervention group
Intervention type: OTHER
Intervention: COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT
Description: there is no interventions to the patients.
Study NCT06523166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Description: TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.
Study NCT06523166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac CTA
Description: Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
Study NCT06621472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrolaminar block technique
Description: patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.
Study NCT06621472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subcostal TAP technique
Description: The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected
Study NCT06621472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic Epidural
Description: Before induction of general anesthesia the epidural catheter was inserted under sterile condition with a loss of resistance technique by an 18G needle at a mid-thoracic level (Th 7-10) to cover the dermatomes innervating the incision in the upper abdomen. The epidural infusion consisting of bupivacaine 1 mg/mL, and fentanyl 2 μg/mL was activated on the attending anesthesiologist's decision. Following the hospital protocols, the infusion rate was initiated at 5-10 mL/h, increased to maximum 15 mL/h if necessary, bolus dose of 5 mL was allowed every 30 minutes.
Study NCT04946370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
Study NCT04946370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
Study NCT04946370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitor
Description: Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
Study NCT04946370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: \[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
Study NCT05629923 — intervention group
Intervention type: DRUG
Intervention: tixagevimab-cilgavimab(AZD7442, AstraZeneca)
Description: In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
Study NCT04798638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets under Fasted Condition - Arm1
Description: Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study NCT04635280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking
Description: A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
Study NCT06636799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling only
Description: In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
Study NCT04798638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets under Fasted Condition - Arm1
Description: Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.